This page shows the latest azacitidine news and features for those working in and with pharma, biotech and healthcare.
Researchers found that Venclyxto (venetoclax) – known as Venclexta in the US – in combination with azacitidine extended overall survival (OS) compared to the azacitidine plus placebo arm. ... The safety profile of the treatment was found to be
a host of other indications, as well as azacitidine betapharm (azacytidine) and azacitidine Mylan (azacitidine) for the treatment of a number of blood cancers.
CC-486 is an oral version of Celgene’s already-marketed chemotherapy Vidaza (azacitidine), which is administered intravenously – it had been a top-selling product for the company, before being hit
Regulatory filings expected in first half of 2020. Celgene’s oral version of acute myeloid leukaemia (AML) chemotherapy azacitidine has hit the target in a phase 3 trial, setting up regulatory ... The formulation – known as CC-486 – is an
The drug gained FDA approval in December 2017. Celgene also received a positive opinion for azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloidleukaemia.
It is being given in combination with Celgene’s Vidaza (azacitidine) and will look at escalating doses of Argenx’ drug, given intravenously, with a standard dose of Vidaza.
More from news
Approximately 2 fully matching, plus 19 partially matching documents found.
The FDA also approved AbbVie and Roche’s Venclexta (venetoclax) with cytarabine or a hypomethylating agent (azacitidine or decitabine) for the exact same indication – adding to the options for this patient
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...